Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
4.55 (USD) • At close September 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Revenue
| 198.772 | 192.64 | 254.382 | 268.682 | 248.168 |
| Cost of Revenue
| 11.314 | 14.796 | 24.282 | 25.629 | 23.364 |
| Gross Profit
| 187.458 | 177.844 | 230.1 | 243.053 | 224.804 |
| Gross Profit Ratio
| 0.943 | 0.923 | 0.905 | 0.905 | 0.906 |
| Reseach & Development Expenses
| 74.431 | 76.823 | 85.77 | 75.363 | 55.577 |
| General & Administrative Expenses
| 0 | 112.383 | 133.885 | 117.347 | 127.91 |
| Selling & Marketing Expenses
| 0 | 0.5 | 2.6 | 6.7 | 12.6 |
| SG&A
| 146.414 | 112.883 | 136.485 | 124.047 | 140.51 |
| Other Expenses
| 7.273 | 2.09 | 1.516 | 1.478 | 1.478 |
| Operating Expenses
| 228.118 | 191.796 | 223.771 | 200.888 | 197.565 |
| Operating Income
| -40.66 | -13.952 | 6.329 | 42.165 | 27.239 |
| Operating Income Ratio
| -0.205 | -0.072 | 0.025 | 0.157 | 0.11 |
| Total Other Income Expenses Net
| 17.739 | 20.291 | 4.971 | 0.199 | 4.416 |
| Income Before Tax
| -22.921 | 6.339 | 11.3 | 42.364 | 31.655 |
| Income Before Tax Ratio
| -0.115 | 0.033 | 0.044 | 0.158 | 0.128 |
| Income Tax Expense
| -4.021 | 3.83 | 5.025 | 9.212 | 8.318 |
| Net Income
| -18.9 | 2.509 | 6.275 | 33.152 | 23.337 |
| Net Income Ratio
| -0.095 | 0.013 | 0.025 | 0.123 | 0.094 |
| EPS
| -0.33 | 0.044 | 0.11 | 0.6 | 0.43 |
| EPS Diluted
| -0.33 | 0.044 | 0.11 | 0.58 | 0.42 |
| EBITDA
| -32.528 | -10.942 | 9.062 | 45.006 | 30.103 |
| EBITDA Ratio
| -0.164 | -0.057 | 0.036 | 0.168 | 0.121 |